Compare Nasdaq Inc (NDAQ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs BIO-TECHNE Corp — how do they compare? Nasdaq Inc trades at $92.37 (market cap $51.63B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Nasdaq Inc is far larger — about 4.5× BIO-TECHNE Corp's market cap, and Nasdaq Inc pays the higher dividend (1.26%). Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 125 Days and BIO-TECHNE Corp for 63 Days on average.
| NDAQ | TECH | |
|---|---|---|
Market Cap | $51.63B | $11.36B |
Volume | 2,668,175 | 5,390,331 |
Sector | Financials | Health |
52-Week High | $100.98 | $72.61 |
52-Week Low | $76.85 | $43.31 |
Typical Hold Time | 125 Days | 63 Days |
Enterprise Value | $58.09B | $11.39B |
Dividend Yield | 1.26% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $91.93, down 0.37% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong fundamentals with 2025 revenue of $8.26 billion and net income of $1.79 billion, yielding a net margin of 21.64%. Recent news highlights growth in its Financial Technology segment, including AI enhancements to the Calypso platform and new client adoptions like HSBC.
The outlook is positive given analyst consensus with a $110.71 price target and 61% buy ratings, though near-term technical weakness and high valuation ratios pose risks. Key catalysts include continued tech adoption and cross-selling, while risks involve market volatility and execution challenges in a competitive landscape.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
